Prometheus Biosciences: Mark Stenhouse

Prometheus Biosciences, a developer of therapeutic and companion diagnostic products for inflammatory bowel disease, has appointed Mark Stenhouse as chief operating officer. Stenhouse previously served as general manager of the screening business at Exact Sciences. He previously spent nearly 30 years at Abbott Laboratories/AbbVie, most recently as vice president of US immunology. He was also vice president and general manager of the gastroenterology franchise, having spent 10 years working in IBD. Stenhouse currently is a member of the board of directors for Phathom Pharmaceuticals.